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Abstract.  Medium conditioned by Chinese hamster 
ovary (CHO) cells transfected with the simian pre-pro- 
TGF/31 cDNA contains high levels of latent TGF/31. 
The amino-terminal  region of the TGF/~I  precursor is 
secreted and can be detected in the conditioned me- 
dium by immunoblotting using peptide antibodies 
specific for amino-terminal  peptides.  Chemical cross- 
linking  of CHO-conditioned medium using bis-(sul- 
fosuccinimidyl)-suberate (BS  3) followed by immunoblot 
analyses indicates that latent recombinant TGF/31 con- 
tains both the cleaved amino-terminal  glycopeptide and 
mature TGF/31 polypeptide in a noncovalent associa- 
tion and that this association confers latency.  The data 
presented here do not support the involvement of a 
unique TGF/3 binding protein(s) in latent recombinant 
TGF/31.  Plasmin treatment of CHO-conditioned me- 
dium resulted in the appearance of TGF/3 competing 
activity. In addition,  immunoblot analysis of plasmin- 
treated CHO-conditioned medium indicates that the 
amino-terminal  glycopeptide is partially degraded and 
that mature TGF/31 is released.  Thus,  activation of la- 
tent TGFB1  may occur by proteolytic nicking within 
the amino-terminal  glycopeptide thereby causing a dis- 
ruption of tertiary structure and noncovalent bonds, 
which results in the release of active, mature TGF/~I. 
Acid activation of latent TGF/~,  in comparison,  ap- 
pears to be due to dissociation of the amino-terminal 
glycopeptide from the mature polypeptide. 
T 
RANSFORMING  growth factor/3 (TGFB) ~  is an impor- 
tant regulator of  cell growth and differentiation. TGF/3 
has been shown to be a potent inhibitor of  proliferation 
of many  cell types, both normal and transformed (Tucker 
et al.,  1984b; Moses et al.,  1985). In addition,  TGF/3 may 
stimulate  growth under  specific  conditions  in certain cell 
types.  The majority of cultured cells studied  to date have 
been shown to secrete TGF/~I in an inactive form (Lawrence 
et al., 1985; Pircher et al., 1986) that neither interacts with 
specific TGF/~ cell surface receptors nor elicits any of the 
known TGF/3-induced biological responses. The presence of 
specific TGF/3 receptors on most cell types (Tucker et al., 
1984a) and the ubiquity of  the TGF/3 molecule itself(Roberts 
et al.,  1983; Moses et al.,  1985) suggest that activation  of 
latent TGF/~ must be an integral component in the sequence 
of events leading  to growth regulation  by TGFB. 
The active 25-kD TGF/3 molecule consists of two identical 
disulfide-linked  12.5-kD polypeptide chains (Assoian et al., 
1983). The 12.5-kD monomer contains 112 amino acids and 
is synthesized  as a larger  pre-pro-TGFffl  molecule of 390 
amino  acid residues as determined by cDNA sequencing 
(Derynck et al.,  1985). The carboxy-terminal  12.5-kD ma- 
ture  peptide  is  proteolyticaUy  cleaved  from  the  amino- 
terminal glycopeptide at arginine 278 (Derynck et al., 1985; 
I.  Abbreviations used in this paper:  BS  3, bis(sulfosuccinimidyl)suberate; 
TGF/3, transforming  growth  factor/3. 
Gentry et al.,  1987).  In addition,  a signal  sequence of 29 
amino acids is cleaved by a signal peptidase during transit 
of the precursor through  the rough  endoplasmic reticulum 
(Gentry et al.,  1988). Other posttranslational  modifications 
of TGF/~ that take place before secretion include glycosyla- 
tion,  mannose-6-phosphorylation  of the glycoprotein and 
disulfide isomerization  (Gentry et al., 1988; Purchi0 et al., 
1988; Brunner et al.,  1988). These events have been desig- 
nated "processing" steps, and, while their order has not been 
well characterized, they are distinct from "activation" events 
that  are required for the generation  of biologically active 
TGF/$ from the latent molecule.  Activation may be achieved 
by extremes of pH or by treatment with selected chaotrophic 
agents,  including  SDS and  urea  (Lawrence et al.,  1985; 
Pireher et al.,  1986). More recently, we have reported pro- 
tease,  specifically  plasmin,  activation  of latent  TGF/3 se- 
creted by fibroblasts (Lyons et al., 1988). Recent findings of 
Sato  and  Rifkin  (1989)  indicate  that  activation  of latent 
TGF/~ occurring  during  co-culture of bovine endothelial 
cells and pericytes is due to plasmin.  This suggests that plas- 
min may be a physiological  activator of latent  TGF/3. 
Chinese hamster ovary (CHO) ceils transfected  with sim- 
ian TGF/~I eDNA secrete 200-1,000-fold more latent TGF/~I 
than  nontransfected  cells providing  an excellent  source of 
material  for use in activation  studies  (Gentry et al.,  1987). 
The overexpression  of latent  recombinant TGF/$1 enabled 
the detection of the amino-terminal  glycopeptide and mature 
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bodies (Gentry et al., 1987; Brunner et al., 1988). The pres- 
ent  study indicates that a  noncovalent association of the 
amino-terminal glycopeptide with the mature TGF/31 poly- 
peptide is responsible for latency of the 25-kD molecule and 
further suggests that proteolytic degradation of the TGF/31 
amino-terminal glycopeptide may provide a means of release 
of the active 25-kD TGF/3 molecule. The results of these ex- 
periments  suggest that plasmin  may degrade the  amino- 
terminal glycopeptide and thereby release active TGF/31. 
Materials and Methods 
Cell Culture and Collection of Conditioned Medium 
CHO cells were transfected with simian pre-pro-TGF/~l and adapted to grow 
in increasing  concentrations of methotrexate  (Gentry et al.,  1987).  For 
these studies, a cloned CHO cell line termed clone 17, was used and propa- 
gated as described (Brunner et al.,  1988).  Serum-free DME containing 
methotrexate (20/~M) was added to confluent cultures and cell-conditioned 
medium was collected after 24 h. Crude-conditioned medium was centri- 
fuged to remove cellular debris and stored at 40C before use to prevent 
spontaneous activation.  Acid activation of conditioned medium was per- 
formed by the addition of HCI to reach pH 1.5 for 1 h. The medium was 
then reneutralized using NaOH and used for biological  and biochemical 
analyses. 
AKR-2B (clone 84A) cells were used as indicator cells in radioreceptor 
assays.  Cultures  were  maintained in McCoy's  5a medium supplemented 
with 5% FCS, 
Radioreceptor  Assay 
TGFI3 radioreceptor assays were performed as previously described (Tucker 
et al., 1984a). Porcine TGF/3 (R & D Systems, Inc., Minneapolis, MN) was 
iodinated using a modified chioramine-T  method (Frolik et al.,  1984) and 
had a specific activity of '~50 Ci/g.  Binding was performed in 1 ml/well 
of binding buffer (PBS, pH 7.4) containing [125I]TGF13 (0.25 ng; ,~,30,000 
cpm). Nonspecific binding was determined in the presence of 30 ng porcine 
TGFI31 and was <25 %. 
Peptide Antibodies 
The synthetic peptide antibodies used in these studies have been character- 
ized previously (Gentry et al., 1987). The antibodies are denoted as follows: 
No.  1125, amino-terminal peptide  sequence  81-96;  No.  7251,  amino- 
terminal  peptide  sequence  225-236;  and  No.  978,  mature  sequence 
369-383. 
Chemical Cross-linking of CHO-conditioned Medium 
CHO-conditioned  medium (100 ILl) was incubated with bis(sulfosuccinimi- 
dyl)suberate (BS  3) (Pierce Chemical Co., Rockford,  IL) at the concentra- 
tions indicated  for 45 min at 22°C.  Medium was then centrifuged  for 15 
min at 12,000 g to remove precipitated material. Equivalent amounts of to- 
tal protein from each treatment relative to that of 100 t~l of untrealed condi- 
tioned medium was determined using a dye-binding assay (Bio-Rad Labora- 
tories,  Richmond,  CA).  Samples  were  dried  and  prepared  for  PAGE 
followed by immunoblot analysis. 
Plasmin Treatment of  Latent TGFI31 
CHO-conditioned medium or latent TGF/31 from human platelets (a girl of 
C.-H.  Heldin) was incubated with plasmin as supplied  (Boehringer Mann- 
heim Diagnostics, Inc., Indianapolis,  IN) at the indicated concentrations for 
2 h at 370C. After incubation, PMSF and aprotinin were added to reach 
a final concentration of 2 mM and 0.55 TIU,  respectively.  As a control, 
serum-free MCDB 402 medium which had not been exposed to cells was 
also incubated with plasmin at 37°C for 2 h at which time protease inhibi- 
tors were added as described. Plasmin-treated conditioned medium (30 t,l), 
latent TGF~I from platelets (30 ng) or control medium was then examined 
for TGF~ competing activity in a radioreceptor assay. Duplicate  samples 
were also dried and prepared for PAGE followed by immunoblot analysis. 
PAGE 
After treatments described elsewhere,  CHO-conditioned medium was sub- 
jected to PAGE using a standard protocol (Laemmli, 1970). Proteins were 
solubilized  in a small volume (20-50 td) of Laemmli sample buffer (62.5 
mM Tris, pH 6.8, 2% SDS,  10% glycerol, 0.01% bromophenoi blue) in the 
presence of absence of 50 mM DTT. The samples were then boiled for 
5 min and loaded on a 7.5-15%  linear gradient polyacrylamide  gel with a 
4% stacking gel. Proteins were electrophoresed at 15 mA/0.75 mm gel for 
4-5 h. Rainbow markers (Amersham Corp., Arlington Heights,  IL) were 
used to determine molecular mass. 
lmmunoblot Analysis 
After electrophoresis,  proteins were transferred from the polyacrylamide 
gel to nitrocellulose  (Schleicher & Schuell,  Keene,  NH) as described by 
Towbin et al. (Towbin et la., 1979). Primary antibodies were used at a I:100 
dilution.  Biotinylated  goat anti-rabbit IgG (Vector Laboratories, Burlin- 
game, CA) was used in combination with an avidin-biotin-alkaline  phospha- 
tase complex (Vector Laboratories).  5-bromo-4-chioro-3-indolyl phosphate 
and nitro blue tetrazolium were used as substrates for color development 
of immune complexes. 
Results 
Effect of  Acid Treatment on Latent 
Recombinant TGF/31 
Medium-conditioned by CHO cells transfected with simian 
pre-pro-TGFB1 cDNA that was acidified as described in Ma- 
terials and Methods contained ,x,1 #g/rnl of TGFj5 competing 
activity as measured in a TGFI3 radioreceptor assay (data not 
shown). This is in agreement with determinations based on 
the inhibition of DNA synthesis in mink lung cells (Gentry 
et al., 1987; 1988). Conditioned medium that had been acid- 
treated was  also analyzed by immunoblotting with either 
amino-terminal (No. 1125) or mature (No. 978) peptide anti- 
bodies (Fig.  1) and compared with CHO-conditioned me- 
dium that was untreated (Fig. 2). Under nonreducing condi- 
tions,  both  amino-terminal  and  mature  TGFI31 peptide 
antibodies detect a  110-kD protein (Fig. 2 A). Only a small 
amount of 25-kD mature TGF~I can be detected as com- 
pared to the intensity of the 12.5-kD band visualized when 
reducing conditions were used (Fig. 2 B). Additional bands 
visualized under reducing conditions include two polypep- 
tides with apparent molecular masses of 55 and 44 kD when 
an amino-terminal peptide antibody was used (Fig. 2 B). 
These polypeptides represent the uncleaved pro-TGF/31 poly- 
peptide (55 kD) and the amino-terminal glycopeptide (44 
kD) as demonstrated by Gentry et al. (1987; 1988). The ma- 
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Figure L  Diagrammatic representation of pre-pro-TGF~l. Impor- 
tant sites and their relative positions along the 390-amino acid se- 
quence of monomeric TGF~l are shown. The signal sequence (res- 
idues  1-29,  stippled box),  the amino-terminal (residues 30-278, 
open box), and mature (residues 279-390, diagonally hatched box) 
regions are indicated. The dibasic cleavage site at residue 278 is in- 
dicated by an arrow. Solid lines above the molecule represent pep- 
tide sequences used for antibody production and the antibody num- 
ber is indicated.  Potential plasmin cleavage sites are indicated 
dots (single Arg residues) or lines (monobasic cleavage sequences, 
Benoit et al.,  1987) below the molecule. 
The Journal of Cell Biology, Volume 1  !0,  1990  1362 Figure 2. Immunoblot analysis of CHO cell-conditioned medium. 
Equal volumes (20/~l) of acid-treated (A) or untreated (N) CHO- 
conditioned medium were subjected to SDS-PAGE  on 7.5-15% lin- 
ear gradient gels. Separated proteins were then transferred to nitro- 
cellulose and probed with peptide antibodies that are specific for 
amino-terminal (No. 1125)  or mature (No. 978) sequences. The mi- 
gration of rainbow molecular mass markers is shown. A, Samples 
electrophoresed under nonreducing conditions; B, Samples electro- 
phoresed under reducing conditions in the presence of  50 mM DTT. 
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Figure 3.  Interpretation of immunoblot analyses. A, Polypeptides 
observed under nonreducing conditions by immunoblot analysis 
and their apparent molecular masses are shown. Carbohydrate moi- 
eties (CHO) are indicated. Interchain disulfide linkages are shown 
as vertical lines, but do not indicate position or number. B, Polypep- 
tides detected under reducing conditions and their apparent molec- 
ular masses are depicted. 
ture sequence peptide antibody recognizes both a  12.5- and 
a 55-kD band,, which further supports the view that the 55- 
kD band represents pro-TGF~l. The presence of this molecu- 
lar form may be the result of incomplete processing because 
of overexpression. 
A diagrammatic representation of the polypeptides iden- 
tiffed by immunoblot analysis with and without reduction is 
shown in Fig. 3. The immunoreactive banding pattern of the 
cell-conditioned medium was the same with or without acid 
treatment. As mature TGF31 polypeptides can be detected 
with or without prior acid treatment of the conditioned me- 
dium,  it appears that the denaturing gel conditions (SDS) 
have the same effect as acid treatment. This is not an unantic- 
ipated result, as Lawrence et al. (1985) had shown that many 
dissociating conditions may lead to activation of latent "I'GF/3. 
Thus, the nature of latent TGFB1 cannot be determined from 
this analysis. The presence of SDS, a dissociating agent, dur- 
ing PAGE leads to the detection of mature TGF/31 polypep- 
tides in untreated cell-conditioned medium.  Furthermore, 
under reducing conditions, a band of 85-90 kD detected by 
the amino-terminal antibody is predicted. However, a dis- 
crete band of such molecular mass was not observed. This 
may be because of the inability of this gel system to ade- 
quately separate broad bands of high molecular mass. 
The intensity of the mature TGF/31 polypeptides detected 
with antibody No. 978 is comparable to that obtained when 
a similar amount (100 ng) of pure, biologically active TGF/~ 
is analyzed under identical conditions (data not shown). The 
mature peptide antibody, No. 978, has greater affinity for the 
reduced,  12.5-kD polypeptide (L.  E.  Gentry, unpublished 
data) which accounts for the apparent inconsistency in the 
relative intensities of the 25- and 12.5-kD bands. Because of 
the glycosylation of the precursor sequence as demonstrated 
by Brunner et al. (1988) several bands (110, 55, and 44 kD) 
appear as broad, heavily stained regions. In contrast, the ma- 
ture TGFt5 polypeptide that does not contain glycosylation 
sites,  is detected as a  sharp, discrete band. 
Cross-linking of CHO-Conditioned Medium 
To determine what proteins may be involved in the latent 
form of TGF~ secreted by the transfected CHO cells, chem- 
ical cross-linking of cell-conditioned medium was carried 
out before electrophoresis (Fig. 4). With increasing concen- 
trations of the cross-linking agent BS  3, there is a shift in the 
molecular mass of polypeptides observed with amino-termi- 
nal and mature sequence peptide antibodies. Under reducing 
conditions (Fig. 4 A), the 55- and 44-kD bands detected with 
an amino-terminal peptide antibody become less intense in 
conjunction with the appearance of a high molecular mass 
('~110-kD) immunoreactive band. This high molecular mass 
band was also detected with the mature peptide antibody and 
coincides with the loss of the 55- and 12.5-kD bands at in- 
creasing concentrations of BS  3 (Fig. 4 A). In addition, tran- 
siently acid-treated conditioned medium was exposed to in- 
creasing concentrations of BS  3 after reneutralization of the 
medium (data not shown). Under these conditions, the ma- 
ture peptide antibody detected a  25-kD peptide at all BS  3 
concentrations. A high molecular mass band ('~110 kD) also 
appeared. 
These results can be compared with cross-linked condi- 
tioned medium analyzed under nonreducing conditions (Fig. 
Lyons et al. Plasmin Activation of Latent TGFB  1363 Figure 4.  Chemical cross-linking of CHO cell-condi- 
tioned medium. Conditioned medium was treated with 
the indicated concentrations of BS  3 for 45 min and sub- 
jected to immunobiot  analysis  using the indicated  peptide 
antibodies. Rainbow molecular mass markers are indi- 
cated. A, Reducing conditions; B, nonreducing condi- 
tions. 
4 B).  In the absence of BS  3, the appearance of the 55-kD 
band suggests that spontaneous reduction has taken place. 
This has been observed previously and is believed to be the 
result  of storage  of conditioned medium  (Gentry et  al., 
1987).  The addition of BS  3 to CHO-conditioned medium, 
however,  yielded similar results to those described above. 
That is, a band of '~110 kD was recognized by both amino- 
terminal and mature peptide antibodies. This high molecular 
mass band represents a complex containing either two pro- 
TGF/31 polypeptides (55 kD), two amino-terminal glycopep- 
tides (44 kD) plus two mature polypeptides (12.5 kD), or a 
combination of these three polypeptides. These data provide 
strong evidence that the latent form involves the association 
of the amino-terminal glycopeptide and mature TGF/31 poly- 
peptide and that there are no additional proteins involved in 
this form of latent TGF/31. Furthermore, these data indicate 
that once dissociated, the latent complex cannot be fully re- 
constituted as detectable quantities of mature TGF/31 were 
observed. 
Plasmin Activation of  Latent TGF{31 
We have previously reported that plasmin, a broad spectrum, 
serine protease, activated 50-60% of the cell-secreted latent 
TGF~ (Lyons et al.,  1988).  A similar study was conducted 
using either  CHO-conditioned medium or  latent TGF~I- 
purified  from human  platelets  (Fig.  5).  In  each  case,  a 
smaller proportion of the latent TGF~I could be activated by 
plasmin than by acid treatment. Previous studies have shown 
that  CHO-conditioned  medium  contained  '~1  ~tg/ml  of 
TGF/31 after acidification as measured by the inhibition of 
mink lung epithelial cells  (Gentry et al.,  1987; 1988)  or 
using a specific TGF/~ radioreceptor assay (data not shown). 
Based on the knowledge that plasmin is not as effective as 
acidification in the activation of latent TGF/g a volume of 
CHO-conditioned medium was chosen (30 td) for plasmin 
treatment that would allow detection of  any resulting biologi- 
cal  activity by  radioreceptor  assay.  Incubation of CHO- 
conditioned medium with increasing concentrations of plas- 
rain resulted in an increase in TGF/3 competing activity. The 
inhibition of p2SI]TGF/3 binding increased to a maximum of 
75 % at a plasmin concentration of 2 U/ml. While quantita- 
tion of active TGF/31 after plasmin treatment is not possible 
from these experiments, it is clear that plasmin activates a 
smaller proportion of  the latent recombinant TGF/31 secreted 
by transfected CHO cells than does acidification. 
Similarly, incubation of latent TGF/31 purified from plate- 
lets with increasing concentrations of plasmin produced an 
increase  in  TGF/3  competing  activity.  For  reasons  cited 
above, the amount of latent platelet TGF/31 used (30 ng) ex- 
ceeded that which  is  needed to  achieve  100%  inhibition 
when acid treated. As seen with CHO-conditioned medium, 
plasmin treatment of  latent platelet TGFfll produced biologi- 
cally active TGF/31. However,  the maximum inhibition of 
binding achieved in these experiments was 60%, indicating 
that only a portion of the acid activatable latent material was 
activated by plasmin. The ability of plasmin to activate only 
a portion of latent TGF/31 from human platelets is in agree- 
ment with results obtained using CliO-conditioned medium. 
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Figure 5.  Radioreceptor  assay of plasmin treated  latent TGF~I. 
Conditioned medium (o) or latent TGF~I from human platelets 
(o) was incubated with increasing  concentrations  ofplasmin for 2 h 
at 37°C. Protease inhibitors were then added to a final concentra- 
tion of 2 mM PMSF and 0.55 TIU aprotinin. Serum-free  MCDB 
402 that had not been exposed to ceils was treated  with plasmin 
(2 U/ml) as a control (11), Assays were performed in triplicate and 
the data have been con~ted by subtraction of nonspecific  binding. 
In this assay, 50% inhibition  of binding  can be achieved with I ng/ 
ml of pure TGF~I. 
The Journal of Cell Biology, Volume 110, 1990  1364 Figure 6. Immunoblot analysis of  plasmin-treated CHO cell-conditioned medium. Conditioned medium was treated with the indicated con- 
centrations of plasmin in a manner identical to that described in Fig. 4. Proteins were then electrophoresed under reducing conditions 
and probed with different peptide antibodies. Plasmin alone (2 U/ml) was examined for its ability to cross react with these peptide antibodies 
as a control (C). The migration of rainbow molecular mass markers are indicated. A, Antibody No. 1125; B, Antibody No. 7251; C, Anti- 
body No. 978. 
Effect of  Plasmin on the TGF(J  l Amino-terminal 
Glycopeptide 
In an attempt to address the question of how plasmin was 
able to activate latent recombinant TGF/31, plasmin-treated 
CHO-conditioned medium was analyzed using immunoblot- 
ting techniques (Fig. 6). Two amino-terminal peptide anti- 
bodies were used to detect changes in immunoreactive poly- 
peptides after plasmin treatment (Fig.  1).  Both antibodies 
show that at the lowest concentration of plasmin used, the 
55-kD band is lost and the 44-kD band becomes more in- 
tense.  This  concentration of plasmin,  however,  produced 
only minimal TGF/~ competing activity when examined by 
radioreceptor assay (Fig.  5).  As noted earlier,  the 55-kD 
band represents pro-TGF/~l.  Thus, it appears that low con- 
centrations of plasmin are able to process pro-TGF/$1 (55 
kD) by proteolytic cleavage at the dibasic cleavage site. This, 
however, does not produce biologically active TGFffl. At 
higher concentrations of plasmin, the intensity of the 44-kD 
band decreased and was eventually undetectable with anti- 
body No.  1125 (Fig. 6 A). An identical immunoblot probed 
with a different amino-terminal specific antibody, No. 7251, 
shows that at higher concentrations of plasmin the 44-kD 
band  is  not lost and additional bands  of lower molecular 
weight appear (Fig. 6 B). Finally, when a similar immuno- 
blot was probed with the mature peptide antibody, No. 978, 
there was an increase in intensity of the 12.5-kD band at the 
lowest concentration of plasmin used (Fig.  6  C).  With in- 
creasing concentrations of plasmin, there was a loss of the 
55-kD  band  while  the  intensity of the  12.5-kD  band  re- 
mained constant.  These results suggest that, at concentra- 
tions of plasmin which produce biological activity, there is 
both release of mature TGF/31 and some degradation of the 
TGF/31 amino-terminal glycopeptide. 
The ability of the amino-terminal peptide antibodies, No. 
1125 and No. 7251, to recognize precursor polypeptides af- 
ter plasmin treatment of latent TGF/31 differs significantly. 
Antibody No. 1125 does not detect a 44-kD band at plasmin 
doses which result in biological activity (Fig. 6 A), while an- 
tibody No.  7251  recognizes a  44-kD band at all plasmin 
doses used in this experiment (Fig. 6 B). This suggests that 
the regions at or near the peptide sequence of the TGF/~I 
amino-terminal glycopeptide used to produce antibody No. 
1125 are susceptible to proteolytic cleavage and that such 
protease action results in a loss of the epitope required for 
recognition by antibody No. 1125. The difference in suscep- 
tibility to protease activity may reflect the conformational 
availability of this region for proteolytic attack and/or repre- 
sent an important functional domain of the TGF/$1 amino- 
terminal glycopeptide. 
Discussion 
All cellular responses to TGF/3 are the consequence of an in- 
teraction of the 25-kD TGF/3 homodimer with its specific 
cell surface receptor. However, platelets as well as a variety 
of cells in culture, release TGF/5 in an inactive form. Most 
cells have been shown to have TGF/3 receptors (Tucker et al., 
1984b);  however, latent TGF/3  is not able to compete for 
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any interaction of  the growth factor with its receptor and thus 
is an important point of control of TGFB function. Under- 
standing the structure and composition of latent TGF/3 will 
provide necessary information for determination of the in 
vivo mechanism of TGF/~ activation. Thus, the emphasis of 
this study was to determine the molecular nature of latent 
TGF/3 and to address potential physiologically relevant meth- 
ods of activation. 
Previous studies by several investigators (Gentry et al., 
1987, 1988; Purchio et al., 1988; Brunner et al., 1988) have 
shown that TGF/~ is synthesized as a larger molecule, con- 
tains a dibasic cleavage site (Fig. I), and is glycosylated at 
sites within the amino-terminal region. The present report 
expands upon these findings to determine the molecular na- 
ture of the latent TGFB1 molecule. Specifically,  acid-acti- 
vated  CHO-conditioned  medium  was  compared  directly 
with untreated cell-conditioned medium using immunoblot- 
ting techniques to determine whether additional material 
would appear in the 25- or 12.5-kD bands upon activation. 
There  was  little difference between acid-treated and un- 
treated cell-conditioned medium in this analysis, indicating 
that denaturing gel conditions (SDS) perform the same func- 
tion as prior acid treatment. Chemical cross-linking experi- 
ments were therefore performed to ascertain the involvement 
of other proteins in the latent molecule. These studies dem- 
onstrate that the latent TGF~ secreted by transfected CHO 
cells contains both the amino-terminal glycopeptide and ma- 
ture TGFBI polypeptide and that no other proteins are re- 
quired for latency.  In addition, when conditioned medium 
was exposed to acid conditions prior to cross-linking, ma- 
ture TGF/~I remained free from the cross-linked complex. 
This supports the hypothesis that mature TGF~I is noncova- 
lently associated with the amino-terminal glycopeptide and 
that following activation by acid treatment, the latent com- 
plex can no longer be completely reconstituted. 
Platelets are a rich source of TGFB and other investigators 
have shown that platelets release TGF/3 in an inactive form 
(Lawrence et al.,  1984; Wakefield et al.,  1988).  The latent 
TGFB released by platelets and characterized by Miyazono 
et al. (1988),  contains both the amino-terminal and mature 
TGFB polypeptides.  The involvement of precursor sequences 
in latent TGFB from human platelets was further established 
by Wakefield et al. (1988) through the use of chemical cross- 
linking techniques. The carbohydrate moieties contained in 
the precursor peptide have recently been shown to be impor- 
tant in rendering platelet TGF/3 inactive (Miyazono and Hel- 
din, 1989), suggesting the involvement of carbohydrate struc- 
tures in the stabilization of the association of  amino-terminal 
and mature TGF/~ peptides in the latent molecule. Unlike 
cell-secreted latent TGFB, however, latent TGF/3 released by 
platelets contains an additional protein that is unrelated to 
the  TGFB polypeptides.  This binding protein appears  to 
be covalently associated through disulfide linkage(s) to the 
amino-terminal glycopeptide of the latent complex. Although 
a  binding protein appears  to be an integral part of latent 
TGF/3 released by platelets, acid activation of this material 
can be achieved, suggesting that dissociation of mature, bio- 
logically active TGFB from this complex is possible. Thus, 
the role of the binding protein in this complex remains un- 
clear. The present study demonstrates that such a binding 
protein is not necessary for latency of CHO cell-secreted 
TGFba. 
Proteolytic activation of latent TGFB in cell-conditioned 
medium has been investigated in an earlier report (Lyons et 
al., 1988).  Plasmin was shown to activate 50-60%  of the 
acid activatable pool of latent TGF/3 secreted by fibroblasts. 
Conditioned medium from TGF/31-transfected  CHO  cells 
was treated with plasmin in this study to determine if the re- 
combinant latent TGF/31 could be similarly activated. While 
quantitation was not possible, activation of recombinant la- 
tent TGF/?I was achieved by plasmin treatment. In addition, 
latent TGF/31 from a different source, human platelets, was 
also activated by the same concentrations of plasmin. Al- 
though latent platelet TGF/31 contains an additional binding 
protein  (Miyazono et al.,  1988),  activation of these two 
different forms of latent TGF/31 by either acidification or 
plasmin treatment indicates that the platelet latent TGF/31 
binding protein has little or no influence on the activation 
processes thus far examined. 
Furthermore, at concentrations of plasmin that did not re- 
sult in biological activity, there was a significant loss in de- 
tection of the 55-kD band (pro-TGFB1 monomer) and an in- 
crease in the intensity of  the 12.5-kD peptide (mature TGFBI 
monomer). This suggests that the dibasic cleavage site within 
the pro-TGF/31 molecule, which separates the amino-terminal 
glycopeptide and mature peptide, may be a preferential site 
for plasmin action. However, proteolytic cleavage at this site 
is not sufficient to produce biological activity, indicating that 
the cleaved mature peptide remains in association with the 
amino-terminal glycopeptide at low plasmin concentrations. 
At higher plasmin concentrations, measurable biological ac- 
tivity was observed and additional bands were detected using 
an amino-terminal glycopeptide antibody for immunoblot 
analysis. This suggests that the appearance of plasmin-gen- 
crated TGF/~ activity is accompanied by proteolytic cleavage 
within the amino-terminal glycopeptide. 
The data presented in this study support the hypothesis of 
proteolytic degradation of the TGF/3 amino-terminal glyco- 
peptide as a physiological mechanism of latent TGFB activa- 
tion. A model of plasmin activation is presented (Fig. 7) and 
compared with acid activation. It should be noted that the la- 
tent molecule (110-kD) is shown to have been cleaved at the 
dibasic cleavage site between the amino-terminal glycopep- 
tide and the mature region. This is believed to occur before 
secretion of the latent complex; however, overexpression of 
pre-pro-TGF/~l  by CHO cells may result in a  significant 
amount of incompletely processed protein. As improper pro- 
cessing is considered to be an artefact of overexpression, 
only molecules that have been cleaved at the dibasic site are 
included in this model of activation of latent TGFB1.  Dis- 
sociation of mature TGFB from the amino-terminal glyco- 
peptide is an essential feature for activation by either acid or 
plasmin. However, plasmin acts by cleaving the amino-ter- 
minal glycopeptide that is postulated to result in a conforma- 
tional change in the amino-terminal glycopeptide such that 
mature TGF/~ is released. In contrast, acid acts by disrupting 
hydrogen and other noncovalent bonds through changes in 
ionic strength without degradation of the amino-terminal 
glycopeptide. 
The importance of  the amino-terminal glycopeptide in sta- 
bilizing the latent form of TGFtffl has been further substanti- 
ated using mutant proteins (Brunner et al., 1989). The sub- 
stitution  of cysteine residues  within  the  amino-terminal 
glycopeptide resulted in the secretion of biologically active 
TGF~. In addition, only monomeric amino-terminal glyco- 
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Amino -Terminal Glvcooeutide  Amino -Terminal Glvcoueotide  Figure  Z Model of acid and plasmin activation of cell-secreted la- 
tent TGF/~I.  Open boxes represent amino-terminal glycopeptides 
and diagonally hatched boxes represent mature polypeptides. Pro- 
cessing has occurred by proteolytic cleavage at the dibasic site (Fig. 
2) and the amino-terminal glycopeptides and mature polypeptides 
remain associated through noncovalent interactions (broken lines). 
Disulfide linkages are represented by $, but do not indicate number 
or position; carbohydrate  moieties (CHO) are indicated. The mo- 
lecular mass of latent  and mature TGFB1  is indicated.  The pre- 
dicted molecular mass of the dissociated amino-terminal glycopep- 
tide is 85-90 kD; however, this molecular form was not separated 
from the 110 kD latent TGFBL The cleaved amino-terminal glyco- 
peptide was not examined under nonreducing conditions. Under re- 
ducing conditions, however, several bands of'~ 25-27 kD were ob- 
served; thus, the predicted molecular mass of the plasmin-cleaved 
amino-terminal glycopeptide is '~50-55  kD. 
peptides  were  observed.  This  study indicates  that  latent 
TGFBI is stabilized by dimerization of the amino-terminal 
glycopcptide and further supports the hypothesis that disrup- 
tion of the amino-terminal glycopeptide will release mature, 
biologically active TGFBI. 
Plasmin has been shown to activate latent TGF~ from sev- 
eral sources. In addition, the activation of latent TGFB dur- 
ing the co-culture of bovine endothelial cells and pericytes 
can be diminished by the addition of a specific plasmin inhib- 
itor to the co-culture system (Sato and Rifkin, 1989).  Fi- 
nally, the ability of TGFB to increase message and activity 
levels of plasminogen activator inhibitor as well as decrease 
plasminogen activator activity (Laiho et al., 1986a, b; Keski- 
Oja et al., 1988), provides an excellent system for the nega- 
tive feedback regulation of TGFB action formerly proposed 
(Lyons et al., 1988).  These data make plasmin an attractive 
candidate for a physiological activator of latent TGFB. 
This study was supported by National Cancer Institute grant CA42572, De- 
partment of Health and Human Services. 
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